IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2023, after market close on Wednesday, March 6, 2024.
Title: | MDxHealth Presents Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call and Webcast |
Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
Date: | March 6, 2024 |
Time: | 4:30pm ET/ 22:30 CET |
Conference Call Dial-in Details: | United States: 1-888-886-7786 Belgium: 0800 76018 |
Conference ID: | 80031769 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1655339&tp_key=a93e4440eb |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About mdxhealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
This email address is being protected from spambots. You need JavaScript enabled to view it.
LifeSci Advisors (IR & PR)
US: +1 949 271 9223
This email address is being protected from spambots. You need JavaScript enabled to view it.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
Last Trade: | US$1.60 |
Daily Change: | 0.06 3.56 |
Daily Volume: | 15,252 |
Market Cap: | US$79.200M |
February 26, 2025 February 12, 2025 January 13, 2025 November 06, 2024 October 14, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load